Combined management report for the financial year 2025	3
Balance sheet as of September 30, 2025	4
Income statement for the financial year from October 1, 2024 to September 30, 2025	5
Notes to the Annual financial statements for the financial year 2025	6
1 General information	6
2 Registration information	6
3 Accounting policies	7
4 Notes to the Balance sheet	10
5 Notes to the Income statement	15
6 Other information	17
7 Executive bodies of the company	21
List of direct and indirect shareholdings of SCHOTT Pharma AG & Co. KGaA as of September 30, 2025 in accordance with section 285(1) no. 11 HGB	23
Responsibility statement	24
Independent auditor's report	25
Imprint	32

COMBINED MANAGEMENT REPORT FOR THE FINANCIAL YEAR 2025

The Management report of SCHOTT Pharma AG & Co. KGaA, Mainz and the Group management report are presented combined, in accordance with section 315(5) in conjunction with section 298(2) of the German Commercial Code (HGB), and published in the Annual report of SCHOTT Pharma AG & Co. KGaA.

The Annual financial statements and the Management report of SCHOTT Pharma AG & Co. KGaA (combined with the Group management report) for the financial year 2025 are submitted to (and published in) the German Company Register (Unternehmensregister), the central platform for making company data publicly available.

Furthermore, the Annual financial statements and the Annual report of SCHOTT Pharma AG & Co. KGaA, Mainz, for the financial year 2025 are available on our website at https://ir.schott-pharma.com/investor-relations/news publications/reports-and-presentations/.

4 Balance sheet as of September 30, 2025

BALANCE SHEET AS OF SEPTEMBER 30, 2025

Assets
(in EUR)	Sep. 30, 2025	Sep. 30, 2024

A. Fixed assets
I. Intangible fixed assets
Purchased concessions, industrial
property rights and similar rights and assets, as well as
licenses in such rights and assets	61,902.37	181,358.42
	61,902.37	181,358.42

II. Property, plant and equipment
1. Land, land rights and buildings	17,885,564.40	10,524,715.53
2. Technical equipment and machinery	74,543,470.15	52,789,371.65
3. Other equipment, operating and office equipment	14,290,812.04	13,061,351.91
4. Advance payments made and assets under construction	37,718,492.68	64,187,350.83
	144,438,339.27	140,562,789.92
III. Financial assets
1. Shares in affiliated companies	482,947,723.81	484,457,723.81
2. Loans to affiliated companies	14,000,000.00	4,000,000.00
3. Joint ventures	4,193,466.48	4,193,466.48
	501,141,190.29	492,651,190.29
	645,641,431.93	633,395,338.63
B. Current assets
I. Inventories
1. Raw materials, consumables, and supplies	7,677,052.16	7,157,515.16
2. Work in progress	243,891.28	1,886,195.61
3. Finished goods and products	6,686,312.55	7,508,696.08
	14,607,255.99	16,552,406.85
II. Receivables and other assets
1. Trade receivables	14,794,614.59	11,409,550.39
2. Receivables from affiliated companies	124,282,875.36	132,606,536.25
3. Receivables from joint ventures	3,411.48	8,606.00
4. Other assets	6,789,683.83	6,987,646.63
	145,870,585.26	151,012,339.27
	160,477,841.25	167,564,746.12
C. Prepaid expenses	515,046.36	638,086.28
Total assets	806,634,319.54	801,598,171.03

		Equity and liabilities
(in EUR)	Sep. 30, 2025	Sep. 30, 2024

A. Equity I. Subscribed capital1	150,614,616.00	150,614,616.00
II. Capital reserve	491,934,852.78	491,934,852.78
III. Net retained profit	86,068,793.85	67,346,528.25
	728,618,262.63	709,895,997.03
B. Provisions
1. Provisions for pensions and
similar commitments	21,391,747.60	21,966,760.60
2. Provisions for taxes	2,395,414.10	11,564,251.00
3. Other provisions	16,488,919.57	20,126,816.56
	40,276,081.27	53,657,828.16
C. Liabilities
1. Advances received on orders	18,971,907.24	19,637,481.78
2. Trade liabilities	7,376,115.33	8,936,931.52
3. Liabilities to affiliated companies	10,641,928.27	8,486,561.66
4. Liabilities to joint ventures	8,454.97	0.00
5. Other liabilities	741,569.83	983,370.88
	37,739,975.64	38,044,345.84

¹ Conditional capital of EUR 25,000k as of September 30, 2025 (previous year: EUR 25,000k).

INCOME STATEMENT FOR THE FINANCIAL YEAR FROM OCTOBER 1, 2024 TO SEPTEMBER 30, 2025

(in EUR)	2025	2024
1. Revenue	187,227,331.92	164,436,236.96
2. Decrease in finished goods and work in progress	-2,566,021.46	-371,830.38
3. Other own work capitalized	35,357.96	0.00
4. Total operating performance	184,696,668.42	164,064,406.58
5. Other operating income	10,818,951.66	10,608,291.99
6. Cost of materials
a) Cost of raw materials, consumables, supplies, and of purchased merchandise	-23,653,328.52	-25,448,816.06
b) Cost of purchased services	-24,981,364.09	-22,228,989.38
	-48,634,692.61	-47,677,805.44
7. Personnel expenses
a) Wages and salaries	-49,254,461.43	-48,877,088.56
b) Social security contributions and expenses for retirement benefits	-10,336,585.95	-12,417,211.80
	-59,591,047.38	-61,294,300.36
8. Amortization, depreciation and impairment of intangible fixed assets and property, plant and equipment	-15,690,044.37	-11,611,625.13
9. Other operating expenses	-60,119,723.01	-65,339,152.99
10. Income from investments	37,469,941.24	60,207,016.39
11. Income from long-term loans	379,721.45	1,608,870.47
12. Other interest and similar income	3,200,768.10	2,876,860.09
13. Impairment of financial assets	-3,760,000.00	-11,100,000.00
14. Interest and similar expenses	-38,104.99	-46,237.76
15. Income taxes	-5,904,959.35	-2,404,078.51
16. Result after taxes	42,827,479.16	39,892,245.33
17. Other taxes	-6,875.00	-6,001.00
18. Profit for the period	42,820,604.16	39,886,244.33
19. Profit carried forward	43,248,189.69	27,460,283.92
20. Net retained profit	86,068,793.85	67,346,528.25

NOTES TO THE ANNUAL FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR 2025

1 GENERAL INFORMATION

The Annual financial statements of SCHOTT Pharma AG & Co. KGaA, Mainz ("SCHOTT Pharma KGaA" or the "Company") as of September 30, 2025 have been prepared in accordance with the provisions of German commercial law for large corporations (sections 242 et seqq. and 264 et seqq. HGB) and the supplementary provisions of the AktG.

SCHOTT Pharma KGaA is a listed partnership limited by shares under German law (Kommanditgesellschaft auf Aktien, KGaA). The shares of SCHOTT Pharma KGaA are admitted to trading on the Regulated Market of the Frankfurt Stock Exchange and simultaneously admitted to the sub-segment of the Frankfurt Stock Exchange's Regulated Market with additional post-admission listing obligations (Prime Standard) under the ticker symbol 1SXP and ISIN DE000A3ENQ51.

The financial year of SCHOTT Pharma KGaA begins on October 1 and ends on September 30 of the following year. The financial year 2025 therefore covers the period from October 1, 2024 to September 30, 2025. The previous year (2024) referred accordingly to the period from October 1, 2023 to September 30, 2024.

The Annual financial statements are prepared in euros. Amounts for the reporting period are shown in thousands of euros (EUR k) in the Notes to the Annual financial statements (the "Notes") unless stated otherwise. To improve transparency, all required disclosures, including "thereof" items, are included in the Notes.

These Annual financial statements of SCHOTT Pharma KGaA comprise the Balance sheet, the Income statement and the Notes. Pursuant to section 315e HGB, as the parent entity SCHOTT Pharma KGaA prepares Consolidated financial statements in accordance with International Financial Reporting Standards (IFRS), as applicable in the European Union. The Management report of SCHOTT Pharma KGaA and the Group management report of SCHOTT Pharma Group as of September 30, 2025 are presented combined, in accordance with section 315(5) in conjunction with section 298(2) HGB.

The Income statement is classified using the nature of expense method pursuant to section 275(2) HGB.

A list of SCHOTT Pharma KGaA's shareholdings is attached to these Notes.

The Annual financial statements were prepared on a going concern basis.

In the financial year 2025, a profit and loss transfer agreement was concluded between SCHOTT Pharma KGaA and SCHOTT Pharma Mexiko GmbH, Mainz. Under this agreement, SCHOTT Pharma Mexiko GmbH, Mainz, is required to directly transfer or offset its profit or loss for the period in terms of commercial law to SCHOTT Pharma KGaA

2 REGISTRATION INFORMATION

The company has its registered office in Mainz, Germany, and is entered under the name of SCHOTT Pharma AG & Co. KGaA in the commercial register of the local court in Mainz under HRB 51230.

3 ACCOUNTING POLICIES

The following material accounting policies, which were unchanged compared to the previous year, apply for the preparation of the Annual financial statements.

Intangible assets acquired for consideration are recognized at cost less accumulated amortization calculated on a straight-line basis – usually over an expected useful life of three years. Internally-generated intangible assets are not capitalized, exercising the option pursuant to section 248(2) sentence 1 HGB.

If impairment is expected to be permanent and exceeds the usual wear and tear, impairment losses are recognized. Amortization of additions to intangible assets is charged pro rata temporis.

Property, plant and equipment is recognized at cost, less depreciation due to wear and tear if they have a limited life. The straight-line method of depreciation is used as a matter of principle. The following expected useful lives are applied for the depreciation of the various groups of property, plant and equipment:

	Years

Land rights and buildings	10 to 14
Technical equipment and machinery	7 to 15
Other equipment, operating and office equipment	3 to 15

Independently usable movable fixed assets with limited useful lives are fully expensed in the year of acquisition if their individual acquisition or production cost does not exceed EUR 250.00. For convenience, such assets with a cost of more than EUR 250.00 but not exceeding EUR 1,000.00 are also recognized in an annual collective item for tax purposes in the statutory balance sheet and depreciated over a period of five years. After full depreciation, the collective item is presented as a disposal in the Statement of changes in fixed assets.

If impairment is expected to be permanent and exceeds the usual wear and tear, impairment losses are recognized. Depreciation of additions to property, plant and equipment is charged pro rata temporis.

The cost of self-constructed property, plant and equipment includes direct costs as well as appropriate portions of the necessary material and production overheads including depreciation, to the extent that this relates to production. Advance payments made on property, plant and equipment are recognized at their nominal value.

Investment grants provided by public-sector authorities to support the acquisition or production of property, plant and equipment are deducted from cost, leading to a corresponding decrease in future depreciation.

Within financial assets, shares in affiliated companies and joint ventures are recognized at cost or at the lower net realizable values if impairment is expected to be permanent. The fair value is calculated based on the discounted cash flow (DCF) model. The cash flows used come from company-specific business planning for a period of three years. Cash flows beyond the three-year period are extrapolated using estimated growth rates. The country-specific weighted discount rate is derived from the return on a risk-adequate alternative investment. If the fair value is lower than the carrying amount, qualitative criteria are used to assess whether the impairment loss is expected to be permanent. Impairment losses are reversed to a maximum of cost if impairment was charged in previous years, and all or some of the reasons for impairment cease to apply in subsequent periods. Loans to affiliated companies are recognized at nominal value less any required loss allowances.

Within inventories, raw materials, consumables and supplies are valued at the lower of average cost calculated as weighted average prices or net realizable value as of the reporting date; inventory range allowances are used in particular due to the turnover rate of inventories.

Finished goods and work in progress are recognized at production cost in accordance with section 255(2) HGB. Production cost includes direct costs and appropriate portions of material and production overheads as well as the share of fixed asset depreciation caused by production. Allowances are recognized to provide for risks resulting from slow-moving goods and reduced usability; the principle of valuation at net realizable value is observed.

The value of products is measured at cost or the lower fair value on the reporting date.

Borrowing costs and general administrative expenses are not included in production cost.

Apart from customary retentions of title, inventories are free from third-party rights.

Receivables and other assets are stated at their nominal value; receivables bearing no interest or interest at a belowmarket rate that are due in more than one year are recognized at their present value. Discounting is performed using an interest rate for the relevant term published by Deutsche Bundesbank. Specific bad debt allowances are recognized to account for identifiable default risks. For general credit risk, a country-specific allowance calculated on a flat-rate basis is recognized and deducted from receivables carried on the Balance sheet.

Prepaid expenses are recognized in the amounts paid in the current financial year that relate to expenses for a certain period following the reporting date.

Subscribed capital is carried at its nominal value.

Provisions for pensions and similar obligations are recognized for three major pension commitments:

The "P 82 old" and "P 82 new" pension schemes are salary-based pension schemes. Under these schemes, the pension benefit increases by a percentage of pensionable remuneration for each year of eligible service; salary components in excess of the income threshold are given a higher weighting.

The pension scheme "VO 2015" as well as the previously applicable pension scheme "VO 2000", which was replaced on 1 October 2015, are defined contribution plans with a dynamic benefit contribution. These are building block schemes, within the scope of which a benefit contribution is determined each year which is then converted into a pension building block using actuarial methods. This pension building block is credited to the employee's individual benefit account. The pension contribution depends on pensionable remuneration and also on SCHOTT AG Group's pre-tax profits.

The currently valid "VO 2015 NEW" pension scheme, which has been applicable for new entrants since November 1, 2015, is a defined contribution plan with a dynamic benefit contribution. Calculation of the benefit contribution is similar to that of "VO 2015". This is awarded to the employee as a minimum capital payment and credited to an individualized securities account within the framework of a Contractual Trust Arrangement (CTA).

From October 1, 2025, the "VO 2015 NEW" pension scheme, including transitional arrangements, will also apply for SCHOTT AG employees on November 1, 2015, the date on which "VO 2015 NEW" came into effect (which was prior to the transfer of operations as part of the spin-off). The spin-off was concluded with effect from October 1, 2021, and the Pharma division, along with all rights and obligations, was transferred from SCHOTT AG, Mainz, Germany, to SCHOTT Pharma KGaA.

Pension commitments are determined on the basis of actuarial calculations using the projected unit credit method and biometric calculation bases in accordance with Prof Klaus Heubeck's Mortality Tables 2018 G. Expected future salary and pension increases are taken into account in calculating the commitments. An annual adjustment of 3.0% (previous year: 3.0%) for salaries and 1.0% (previous year: 1.0%) for pension commitments subject to a guaranteed adjustment, as well as 2.25% (previous year: 2.25%) for all other pension commitments, is currently assumed, based on internal data from previous years and the expected future assessment basis for the development of inflation. The determination of pension commitments also factors in an annual increase in the income threshold of 3.0% (previous year: 1.5%) and an employee turnover rate of 2.0% p.a. (previous year: 2.0%). The ten-year average interest rate to be used as a basis for the valuation of pension commitments in accordance with section 253(2) HGB was 2.02% as of September 30, 2025 (previous year: 1.87%); this is the interest rate for a remaining term of 15 years as determined by Deutsche Bundesbank. The seven-year average interest rate was 2.15% as of September 30, 2025 (previous year: 1.91%).

The plan assets managed in the form of a CTA are offset against the underlying commitments in accordance with section 246(2) sentence 2 HGB. In order to fulfill the company's pension obligations to employees, funds are invested in separate securities investment funds that are protected against claims by other creditors and are carried at fair value. The resulting net obligation is recognized under provisions. Net income and expenses from plan assets are offset against the interest portion of the corresponding obligation in the net interest result.

The pension provisions for employee-funded deferred compensation commitments are also based on the ten-year average interest rate of 2.02% as of September 30, 2025 (previous year: 1.87%), a pension increase of 1.0% (previous year: 1.0%) and an employee turnover rate of 2.0% (previous year: 2.0%). Employer's pension liability insurance policies taken out for these provisions are pledged to creditors. Accordingly, the obligations and the cash surrender value of the employer's pension liability insurance policies (fair value) are netted pursuant to section 246(2) sentence 2 HGB.

Tax provisions and other provisions account for all identifiable risks, uncertain obligations and potential losses from pending transactions. They are recognized at the settlement value deemed necessary according to prudent business judgment to fulfill future payment obligations. Future price and cost increases are taken into consideration if there is sufficient objective evidence that such increases will occur. Provisions with a remaining term of more than one year are discounted using the average market interest rate of the past seven financial years for their respective remaining term.

Provisions for anniversary and phased retirement obligations shown under other provisions are valued at the sevenyear average interest rate of 2.15% (previous year: 1.91%) calculated by Deutsche Bundesbank. Pursuant to section 246(2) sentence 2 HGB, provisions for phased retirement obligations are offset against the related plan assets.

Liabilities are recognized at their respective settlement values.

To determine deferred taxes arising due to temporary or quasi-permanent differences between the carrying amounts of assets, liabilities, prepaid expenses and deferred income in the statutory accounts and their tax bases or due to tax loss carryforwards, these differences are valued using the company-specific tax rates at the time they reverse; the amounts of any resulting tax charge or benefit are not discounted. SCHOTT Pharma KGaA does not only include differences from its own balance sheet items, but also those at subsidiaries. Deferred tax assets and liabilities are offset. The option to recognize net deferred tax assets in excess of deferred tax liabilities was not exercised.

Foreign currency receivables and payables are valued in euros using the mid-market spot rate on the transaction date. They are translated at the mid-market spot rate on the reporting date. Losses from exchange rate fluctuations are accounted for, while gains are only recognized if they relate to receivables or payables with a remaining term of up to one year. Both realized and unrealized gains and losses from the translation of foreign currency transactions into local currency are recognized in the Income statement under "Other operating income" or "Other operating expenses", as well as in the associated "thereof" items in the Notes.

Revenue from the sale of goods is recognized as soon as the material risks and rewards of ownership have passed to the buyer and the amount of revenue to be recognized can be reliably measured. Revenue from services is recognized as soon as the service has been rendered.

The fair value of derivative financial instruments is determined on the reporting date based on current market data, strictly at the lower of cost or market. Provisions for potential losses are recognized for unrealized losses, while unrealized gains are not accounted for.

4 NOTES TO THE BALANCE SHEET

Fixed assets

The following overview outlines the development of individual fixed asset items in the financial year from October 1, 2024 to September 30, 2025, including depreciation, amortization and impairment losses for the financial year.

In the reporting year, there were additions to shares in affiliated companies of EUR 2,250k, reflecting a capital increase at our subsidiary SCHOTT Pharma France SAS, Colombes, France.

The impairment losses on shares in affiliated companies recorded in the financial year of EUR 3,760k relate to the adjustment of the shares in Schott Pharma France SAS, Colombes, France to their lower fair value on the reporting date.

Additions to loans to affiliated companies of EUR 11,000k and disposals of EUR 1,000k were posted in the reporting year. These changes result from further loans granted to or repaid by our subsidiary SCHOTT PHARMA D.O.O. JAGODINA, Jagodina, Serbia.

Notes to the Annual financial statements for the financial year 2025 11

Statement of changes in fixed assets for the financial year from October 1, 2024 to September 30, 2025

		Cost					Accumulated depreciation and impairment					Carrying amounts
	(in EUR)	Balance as of Oct. 1, 2024	Additions	Reclassifications	Disposals	Balance as of Sep. 30, 2025	Balance as of Oct. 1, 2024	Additions	Disposals	Balance as of Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2024
I.	Intangible fixed assets
1.	Purchased concessions, industrial property rights and similar rights and assets, as well as licenses in such
	rights and assets	1,698,168.87	18,548.40	25,490.26	0.00	1,742,207.53	-1,516,810.45	-163,494.71	0.00	-1,680,305.16	61,902.37	181,358.42
		1,698,168.87	18,548.40	25,490.26	0.00	1,742,207.53	-1,516,810.45	-163,494.71	0.00	-1,680,305.16	61,902.37	181,358.42
II.	Property, plant and equipment
1.	Land, land rights and buildings	13,095,429.75	122,357.60	9,227,801.13	0.00	22,445,588.48	-2,570,714.22	-1,989,309.86	0.00	-4,560,024.08	17,885,564.40	10,524,715.53
2.	Technical equipment and machinery	103,964,629.00	8,762,496.62	23,155,609.94	-2,762,955.11	133,119,780.45	-51,175,257.35	-9,945,660.94	2,544,607.99	-58,576,310.30	74,543,470.15	52,789,371.65
3.	Other equipment, operating and office equipment	25,879,087.53	1,086,768.69	3,751,906.76	-373,379.92	30,344,383.06	-12,817,735.62	-3,591,578.86	355,743.46	-16,053,571.02	14,290,812.04	13,061,351.91
4.	Advance payments made and assets under
	construction	64,187,350.83	9,691,949.94	-36,160,808.09	0.00	37,718,492.68	0.00	0.00	0.00	0.00	37,718,492.68	64,187,350.83
		207,126,497.11	19,663,572.85	-25,490.26	-3,136,335.03	223,628,244.67	-66,563,707.19	- 15,526,549.66	2,900,351.45	-79,189,905.40	144,438,339.27	140,562,789.92
	III. Financial assets
1.	Shares in affiliated companies	607,007,723.81	2,250,000.00	0.00	0.00	609,257,723.81	-122,550,000.00	-3,760,000.00	0.00	-126,310,000.00	482,947,723.81	484,457,723.81
2.	Loans to affiliated companies	4,000,000.00	11,000,000.00	0.00	-1,000,000.00	14,000,000.00	0.00	0.00	0.00	0.00	14,000,000.00	4,000,000.00
3.	Joint ventures	4,193,466.48	0.00	0.00	0.00	4,193,466.48	0.00	0.00	0.00	0.00	4,193,466.48	4,193,466.48
		615,201,190.29	13,250,000.00	0.00	-1,000,000.00	627,451,190.29	-122,550,000.00	-3,760,000.00	0.00	-126,310,000.00	501,141,190.29	492,651,190.29
		824,025,856.27	32,932,121.25	0.00	-4,136,335.03	852,821,642.49	-190,630,517.64	- 19,450,044.37	2,900,351.45	-207,180,210.56	645,641,431.93	633,395,338.63

Receivables and other assets

Receivables and other assets are broken down as follows:

(in EUR k)	Sep. 30, 2025	Sep. 30, 2024
Trade receivables	14,795	11,410
(thereof due in more than one year)	0	0
Receivables from affiliated companies	124,283	132,607
(thereof due in more than one year)	0	0
Receivables from joint ventures	3	9
(thereof due in more than one year)	0	0
Other assets	6,790	6,988
(thereof due in more than one year)	0	0
	145,871	151,012

Receivables from affiliated companies as of September 30, 2025 comprised trade receivables of EUR 30,758k (previous year EUR 23,153k) and the cash pool receivable from SCHOTT AG of EUR 93,525k (previous year: EUR 109,454k).

As of the reporting date, there were receivables of EUR 326k from the general partner SCHOTT Pharma Management AG, Mainz, in connection with the settlement of claims for the reimbursement of expenses. In the previous year, liabilities in this regard amounted to EUR 342k.

Other assets amount to EUR 6,790k (previous year: EUR 6,988k). essentially relate to value-added tax and income tax refund claims for the financial years 2024 and 2025.

Deferred tax assets

Deferred tax assets and liabilities arise essentially from different carrying amounts of non-current pension provisions as well as other provisions. Overall, deferred tax assets more than offset deferred tax liabilities. The resulting net deferred tax asset is not recognized, exercising the option provided by section 274(1) sentence 2 HGB.

Deferred taxes are measured using the tax rates applicable at the time the differences are expected to be reduced. Due to the gradual reduction of the corporate income tax rate from 15% to 10% in the assessment years 2028 to 2032, tax rates of between 30.4% (in the event of a reduction in assessment years up to 2027) and 25.1% (in the event of a reduction in assessment years from 2032 onwards) were used (previous year: 28.3%).

Equity

Share capital amounted to EUR 150,615k and the capital reserves to EUR 491,935k as of the reporting date.

As of the reporting date, subscribed capital was divided into 150,614,616 ordinary bearer shares with no-par value and a notional interest of EUR 1.00 each in the share capital. All shares are fully paid-in.

The Annual general meeting on June 20, 2023 authorized the Management board, with the approval of the Supervisory board, to increase the share capital of SCHOTT Pharma KGaA, until June 19, 2028 by up to a total of EUR 50,000k through one or more issues of new no-par value bearer shares in exchange for cash or non-cash contributions (Authorized capital). Shareholders will generally be granted subscription rights.

The Annual general meeting on June 20, 2023 also authorized the Management board, with the approval of the Supervisory board, to issue bearer and/or registered convertible bonds and/or bonds with warrants (or a combination of such instruments - collectively referred to below as "bonds") with a total principal amount of up to EUR 750,000k with or without a limited term, until June 19, 2028 and to grant holders or creditors of such bonds conversion or option rights, respectively, to acquire new no-par value bearer shares in the company representing a notional interest in the share capital of up to EUR°25,000k, as stipulated in detail in the terms and conditions of these bonds (Conditional capital).

The Management board did not make use of these authorizations in the financial year 2025.

The Annual general meeting on February 4, 2025 resolved to appropriate the previous year's net retained profit (Bilanzgewinn) of EUR 67,347k to distribute dividends of EUR 24,098k (EUR 0.16 per no-par value share) and to carry forward the remainder of EUR 43,249k to new account.

The following table summarizes the development of net retained profit:

(in EUR k)	2025

Net retained profit as of October 1, 2024	67,347
Dividends for the financial year 2024	-24,098
Profit for the period – financial year 2025	42,821
Net retained profit as of September 30, 2025	86,069

Disclosures on non-distributable amounts

The table below summarizes the determination of the maximum distributable amount considering sections 253(6) sentence 2 and 268(8) HGB:

(in EUR k)	Sep. 30, 2025
Net retained profit as of September 30, 2025	86,069
= Maximum distributable amount as of September 30, 2025 before consideration of sections 253(6) sentence 2 and 268(8) HGB	86,069
– Non-distributable amount due to the difference between the 10-year average interest rate and the 7-year average interest rate	0
– Non-distributable amount due to the measurement of assets at fair value	-751
= Maximum distributable amount as of September 30, 2025 considering sections 253(6) sentence 2 and 268(8) HGB	85,318

The difference in accordance with section 253(6) sentence 2 HGB between the amount of pension provisions discounted at the relevant average market interest rate for the last ten financial years and the amount of pension provisions discounted at the average market interest rate for the last seven financial years amounts to EUR -799k. As the pension provision calculated based on the average interest rate for the last ten years exceeds the amount calculated based on the average interest rate for the last seven years, there is no ban on distributions.

Pursuant to section 268(8) HGB, an amount of EUR 751k is subject to a ban on distributions as the fair value of the plan assets exceeds their cost. The resulting book gain comes to EUR 1,079k. Deferred tax liabilities of EUR 328k were deducted from this amount.

Provisions for pensions and similar commitments

Pension provisions include commitments from current pensions as well as company- and employee-funded pension entitlements.

Assets which serve exclusively to fulfill the pension commitments and which are protected against claims asserted by all other creditors (plan assets as defined by section 246(2) sentence 2 HGB) are recognized at fair value and offset against the settlement value of pension obligations.

Amounts offset in the Balance sheet as of the reporting date:

(in EUR k)	Sep. 30, 2025	Sep. 30, 2024

Settlement value of pensions and similar obligations	35,177	34,302
Fair value of plan assets	13,785	12,335
Provisions for pensions and similar commitments	21,392	21,967
Cost of plan assets	12,780	11,711

Plan assets in Germany are managed mainly in the form of a CTA.

Under the CTA, assets are transferred to a trust association, which in turn transfers the funds it receives to another trustee (custodian). This custodian is obliged to manage and invest the funds it receives solely for the company in accordance with an investment management agreement. Investments are made via special fund mandates with external asset managers. These mandates are mixed funds that invest in equities and bonds, and are managed by asset managers in accordance with prescribed investment guidelines, including a defined value protection strategy.

Effects from changes in the discount rate are recognized in the net interest result. Of the interest portion of EUR -322k included in reversals of pension provisions (previous year: additions of EUR 134k), EUR 643k (previous year: EUR 551k) relates to expenses arising from discounting and EUR -965k (previous year: EUR -417k) to income arising from the change in the discount rate. Net income and expenses from plan assets are offset against the interest portion of reversals of/additions to pension provisions under the net interest result.

The following amounts were offset and reported under "Other interest and similar income":

(in EUR k)	2025	2024

Interest portion of additions to pension provisions	-322	134
Net income/expenses from plan assets	-381	-1,149
Balance after offsetting	-703	-1,015

Provisions for taxes

This item comprises amounts for taxes in the financial years 2022, 2023 and 2025 that have not yet been finally assessed. The decrease compared to the previous year resulted from tax payments for the financial years 2022 and 2023.

Other provisions

Other provisions primarily include amounts for personnel-related obligations as well as provisions for potential losses from derivative financial instruments, provisions for outstanding supplier invoices, provisions for auditing the annual and consolidated financial statements and provisions for warranties. The decrease compared to the previous year is mainly due to lower provisions for potential losses from derivative financial instruments as well as lower personnel obligations.

In accordance with section 246(2) sentence 2 HGB, provisions for phased retirement obligations were offset against the related plan assets.

Amounts offset in the Balance sheet as of the reporting date:

(in EUR k)	Sep. 30, 2025	Sep. 30, 2024

Settlement value of phased retirement obligations	883	1,006
Fair value of plan assets	-722	-722
Provisions for phased retirement obligations	161	284
Cost of plan assets	-722	-722

Liabilities

Liabilities have the following remaining terms:

			Sep. 30, 2025			Sep. 30, 2024
	Thereof	Thereof	Thereof	Total	Thereof	Thereof	Thereof	Total
	with a	with a	with a		with a	with a	with a
	remaining	remaining	remaining		remaining	remaining	remaining
	term of	term of	term of		term of	term of	term of
	up to one	one to	more than		up to one	one to	more than
(in EUR k)	year	five years	five years		year	five years	five years
Advances received on orders	4,550	10,299	4,123	18,972	4,381	10,308	4,948	19,637
Trade liabilities	7,353	23	0	7,376	8,763	174	0	8,937
Liabilities to affiliated companies	10,642	0	0	10,642	8,487	0	0	8,487
Liabilities to joint ventures	8	0	0	8	0	0	0	0
Other liabilities	742	0	0	742	983	0	0	983
(thereof for taxes)	(585)	0	0	(585)	(748)	0	0	(748)
(thereof for social security)	(76)	0	0	(76)	(60)	0	0	(60)
	23,295	10,322	4,123	37,740	22,614	10,482	4,948	38,044

As in the previous year, all of the liabilities to affiliated companies relate to trade payables.

Other liabilities amount to EUR 742k (previous year: EUR 983k) and mainly relate to liabilities arising from income tax on wages and salaries and church tax.

No liabilities were secured as of the reporting date.

5 NOTES TO THE INCOME STATEMENT

Revenue

Revenue is broken down by area of activity as follows:

(in EUR k)	2025	2024

Sale of pharmaceutical packaging	96,618	87,330
Contract manufacturing	42,645	36,066
Other	47,964	41,040
	187,227	164,436

Non-sterile vials account for almost all of the revenue from the sale of pharmaceutical packaging.

Revenue from contract manufacturing is fully attributable to contract manufacturing services provided to SCHOTT Pharma Schweiz AG, St Gallen, Switzerland. Our contract manufacturing services were commissioned exclusively for sterile polymer syringes.

Revenue recognized under "Other" mainly arose from rendering services, charging brand license fees and passing on overhead costs to affiliated companies.

Revenue is broken down by geographical markets as follows:

(in EUR k)	2025	2024
Germany	20,689	21,198
EMEA (excluding Germany)	114,585	104,273
Asia and South Pacific	22,238	17,852
North America	25,829	17,757
South America	3,886	3,356
	187,227	164,436

Other operating income

Other operating income of EUR 10,819k (previous year: EUR 10,608k) mainly includes currency and exchange rate gains of EUR 6,340k (previous year: EUR 6,613k) as well as income from reimbursement of costs of EUR 2,146k (previous year: EUR 2,325k) to SCHOTT Group companies. Reimbursed costs in the financial year 2025 were incurred in connection with renovation work on the leased manufacturing building. In the previous year, these costs related to the IPO.

Prior-period income of EUR 2,170k (previous year: EUR 1,651k) comprises EUR 681k (previous year: EUR 602k) related to the reversal of provisions, EUR 1,266k (previous year: EUR 1,031k) related to the reversal of loss allowances on receivables and EUR 223k (previous year: EUR 18k) related to book gains from the sale of fixed assets. Income from the reversal of provisions relates to various individual items.

Personnel expenses

EUR 1,477k (previous year: EUR 4,054k) of the personnel expenses reported relates to expenses for retirement benefits. The interest portion of additions to pension provisions is not recognized as personnel expenses; this is presented under the net interest result.

Amortization, depreciation and impairment of intangible fixed assets and property, plant and equipment Amortization and depreciation of intangible fixed assets and property, plant and equipment include impairment losses of EUR 331k (previous year: EUR 0k).

Other operating expenses

Other operating expenses include EUR 27,184k (previous year: EUR 28,358k) in selling, general administrative and maintenance expenses, EUR 20,211k (previous year: EUR 19,386k) in expenses for services and EUR 6,005k (previous year: EUR 5,309k) in lease expenses.

Other operating expenses also include EUR 51k (previous year: EUR 345k) in additions to other provisions, EUR 755k (previous year: EUR 3,215k) in loss allowances on receivables and EUR 28k (previous year: EUR 93k) in prior-period unrealized losses on the disposal of assets.

In addition, currency and exchange rate losses of EUR 5,885k (previous year: EUR 8,633k) were reported as other operating expenses.

Income from investments

Income from investments of EUR 35,209k (previous year EUR 57,957k) resulted from dividend income received from affiliated companies in Switzerland, Brazil, Indonesia and Colombia; EUR 2,250k (previous year: EUR 2.250k) related to dividend income received from our joint venture in Italy. EUR 11k (previous year: EUR 0k) also resulted from the profit and loss transfer agreement newly concluded in the reporting year between SCHOTT Pharma KGaA and SCHOTT Pharma Mexiko GmbH, Mainz.

Income from long-term loans

Income from long-term loans is attributable in full to the loans granted to an affiliated company in Serbia.

Impairment of financial assets

The impairment losses on financial assets of EUR 3,760k (previous year: EUR 11,100k) relate to the writedown of shares in SCHOTT Pharma France SAS, Colombes, France (previous year: SCHOTT Pharma USA, Inc., Lebanon, USA) to their lower fair value.

Net interest result

(in EUR k)	2025	2024

Other interest and similar income	3,201	2,877
(thereof from affiliated companies)	2,490	1,850
(of which income from dissolution)	322	0
(thereof expenses from discounting)	0	-134
(thereof net income/expenses from plan assets)	381	1,149
Interest and similar expenses	-38	-46
(thereof to affiliated companies)	0	-34

Net income and expenses from plan assets are offset against the interest portion of reversals of or additions to pension provisions under the net interest result.

Income taxes

Income taxes amounting to EUR 5,905k (previous year: EUR 2,404k) mainly relate to trade and corporation tax as well as foreign withholding taxes for the financial year 2025.

Income taxes do not include any income or expenses from deferred taxes.

The rules on global minimum taxation (Pillar Two) apply to SCHOTT Pharma KGaA for the first time in the financial year 2025. As a domestic constituent entity and partially-owned parent entity (POPE), SCHOTT Pharma KGaA belongs to its ultimate parent entity (UPE) SCHOTT AG, which, due to its tax domicile in Germany, falls within the scope of this act. As UPE of SCHOTT Group, SCHOTT AG is obliged to submit the legally required minimum tax return, to calculate the tax and, if necessary, to pay any top-up taxes. This also includes those calculations that relate to SCHOTT Pharma KGaA as the POPE and the domestic and foreign constituent entities it holds. The minimum rate of tax within the meaning of the act is 15%.

Where top-up taxes arise for jurisdictions that concern SCHOTT Pharma KGaA or one of its constituent entities and that have not already been settled through the payment of qualified domestic top-up taxes, these are charged by SCHOTT AG to SCHOTT Pharma KGaA. These allocations are included as income taxes in the financial statements of SCHOTT Pharma KGaA.

As the respective countries have introduced qualified domestic top-up taxes, no top-up taxes were attributable to SCHOTT Pharma KGaA in the financial year 2025.

6 OTHER INFORMATION

Derivative financial instruments

The company held the following derivative financial instruments as of the reporting date:

	Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2025
(in EUR k)	Nominal amount	Carrying amount	Fair value

Forward foreign exchange contracts	292,487	-1,860	4,133

Nominal amounts reflect the unnetted total of all derivative financial contracts bought and sold. The carrying amount is the lower of cost or fair value. Negative carrying amounts of forward contracts are included in the Balance sheet item "Other provisions." The fair value of the forward foreign exchange contracts is determined using current spot rates and corresponding forward premiums or discounts (spreads). The relevant market data observed on the reporting date are used as input parameters for the models. Forward contracts were concluded primarily in US dollars (USD), Swiss francs (CHF), Chinese renminbi (CNY), Hungarian forint (HUF) and Mexican pesos (MXN).

Contingencies

The following contingent liabilities existed as of the reporting date:

(in EUR k)	Sep. 30, 2025	Sep. 30, 2024

Guarantees	46,458	39,624
(thereof in favor of affiliated companies)	28,893	38,264

Together with SCHOTT Group Treasury, SCHOTT Pharma KGaA's Finance department continuously monitors and assesses contingent liabilities entered into. As of September 30, 2025 and up to the date of preparation of the Annual financial statements, the Management board assumes that the respective principal debtors will honor their obligations. This assessment is based on the expected positive business performance and the sufficient capitalization of the companies concerned.

The risk of drawdowns on contingent liabilities was deemed to be low.

Other financial obligations/Off-balance sheet transactions

Expenses from rental and lease agreements for land, buildings, technical equipment and operating equipment as well as from significant service agreements totaled EUR 6,921k in the financial year (previous year: EUR 6,345k), of which EUR 4,214k (previous year: EUR 3,991k) was attributable to affiliated companies. The expected future minimum payments from existing rental and lease agreements and significant service agreements totaled EUR 32,940k as of the reporting date (thereof EUR 6,411k for the next 12 months, thereof EUR 8,433k with a remaining term of more than five years); this includes EUR 30,644k to affiliated companies (thereof EUR 4,301k for the next 12 months, thereof EUR 8,433k with a remaining term of more than five years).

The terms of these agreements expire between the financial years 2026 and 2032. These rental and lease agreements generally serve to improve liquidity and reduce total assets. Rental and lease agreements concluded at customary conditions do not give rise to any specific risks.

As of the reporting date, obligations from purchase commitments for capital expenditure projects amounted to EUR 10,330k (previous year: EUR 21,569k), of which EUR 1,685k (previous year: EUR 1,840k) related to affiliated companies.

Other financial obligations thus totaled EUR 43,270k (previous year: EUR 58,304k), EUR 32,329k (previous year: EUR 36,692k) related to affiliated companies.

Average number of employees

The average number of people employed by SCHOTT Pharma KGaA in the financial year was as follows:

	2025	2024

Wage earners	360	398
Salaried employees	301	282
	661	680

Auditor's fee

The auditor of the Annual financial statements of SCHOTT Pharma KGaA and SCHOTT Pharma Group is KPMG AG Wirtschaftsprüfungsgesellschaft, Frankfurt am Main. The auditing fees related to the audit of the Consolidated financial statements and the audit of the Annual financial statements of SCHOTT Pharma KGaA and its subsidiaries, and the review of the Condensed interim consolidated financial statements as of March 31, 2025. In addition, the amount also includes fees for the audit of the report on relationships with affiliated companies, the assessment of the early warning system and the audit of the electronic versions of the financial statements and management reports (ESEF).

Other assurance services relate to the review of the Non-financial statement and the Renumeration report, as well as other assurance services required by law, contractually agreed or commissioned on a voluntary basis.

The disclosures on the fee paid to the auditor, pursuant to section 285 no. 17 HGB, for services rendered to SCHOTT Pharma KGaA are included in the Notes to the Consolidated financial statements of SCHOTT Pharma KGaA.

Remuneration of the Management board and the Supervisory board

Remuneration of the members of the Management board totaled EUR 1,726k in the financial year 2025 (previous year: EUR 1,966k). This figure includes share-based remuneration granted in the financial year with a fair value of EUR 558k at the time it was granted (previous year: EUR 507k) for a total of 17,937 (previous year: 16,307) performance shares granted. The tranche granted in the financial year 2025 covers the performance period from October 1, 2024 to September 30, 2028.

The remuneration of the members of the Supervisory board of SCHOTT Pharma KGaA comprises a fixed remuneration as well as additional remuneration for work in committees, and amounted to EUR 326k in the financial year 2025 (previous year: EUR 340k).

The remuneration of the members of the Supervisory board of SCHOTT Pharma Management AG exclusively comprises a fixed remuneration and amounted to EUR 73k in the financial year 2025 (previous year: EUR 80k).

The basic principles of the remuneration system and individual remuneration amounts for members of the Management board and the Supervisory board are summarized in the Remuneration report.

The obligation for paying remuneration to the Management board members lies with SCHOTT Pharma Management AG. SCHOTT Pharma Management AG, however, is entitled to receive compensation from SCHOTT Pharma KGaA for all expenses associated with the management of the Company's business, including the remuneration paid to members of its executive bodies. Accordingly, remuneration for the members of SCHOTT Pharma Management AG's Management board and Supervisory board was charged to SCHOTT Pharma KGaA. As this means that SCHOTT Pharma KGaA bears the obligation from an economic perspective and effectively benefits from the work of the Management board members, all provisions and accrued liabilities related to Management board remuneration were also recognized at the level of SCHOTT Pharma KGaA.

No loans or advances were granted, or subsidies paid, to members of the Management board or the Supervisory board. Furthermore, the Company has not entered into any contingent liabilities in favor of members of the Management board or the Supervisory board.

Related party transactions

No significant transactions with related parties were entered into on terms other than arm's length.

General partner

SCHOTT Pharma Management AG, having its registered office in Mainz and subscribed capital of EUR 50k, is the general partner of SCHOTT Pharma KGaA.

38 WpHG

Sections 33, 34, 38 WpHG

Consolidated financial statements

As the parent company, SCHOTT AG, Hattenbergstrasse 10, 55122 Mainz, Germany, prepares Consolidated financial statements as of September 30, 2025 for the largest group of consolidated companies, in which SCHOTT Pharma KGaA is included. The Consolidated financial statements of SCHOTT AG are published on its website and in the German Company Register (Unternehmensregister).

Pursuant to section 315e(1) HGB, as the parent company, SCHOTT Pharma KGaA prepares Consolidated financial statements for the smallest group of consolidated companies based on International Financial Reporting Standards (IFRS) as applicable in the European Union. The Annual financial statements, the Management report of SCHOTT Pharma KGaA (which is combined with the Group management report) and the Consolidated financial statements of SCHOTT Pharma KGaA are published in the electronic Company Register; in addition, they are available on our website at https://ir.schott-pharma.com/investor-relations/news-publications/reports-and presentations/.

Declaration of Compliance pursuant to section 161 AktG

The Management board and the Supervisory board issued the Declaration of Conformity pursuant to section 161 AktG in September 2025 and subsequently made it permanently available to the public on the website of SCHOTT Pharma KGaA, at https://ir.schott-pharma.com/investor-relations/corporate-governance/compliance statement/.

Notifications of shareholdings in SCHOTT Pharma AG & Co. KGaA

As of September 30, 2025, SCHOTT Pharma KGaA had received notifications regarding shareholdings subject to disclosure requirements pursuant to section 160(1) no. 8 AktG as shown in the following table. Where multiple voting rights thresholds were reached, the most recent notification which led to a threshold being reached is shown. All voting rights notifications can be viewed on our website at https://www.schott-pharma.com/investor relations/share/voting-rights-notifications/. Please note that the disclosures on shareholdings and voting rights may have become outdated in the meantime.

structure
						Share of voting rights
Entity subject to the reporting obligation	Registered office	Date of notification	Date of threshold being reached	Threshold in %	in %	in absolute terms	Voting rights attributable pursuant to the German Securities Trading Act (WpHG)
SCHOTT Glaswerke
Beteiligungs- und	Mainz,						Sections 33
Export GmbH	Germany	Sep 28, 2023	Sep 27, 2023	75.0%	77.00%	115,973,254	and 34 WpHG
State of Qatar	Doha, Qatar	Oct 3, 2023	Oct 2, 2023	3.0%	4.92%	7,407,407	Sections 33 and 34 WpHG
T. Rowe Price	Baltimore,						Sections 33, 34,

Appropriation of profits

Shareholder

Group, Inc.

The Capital Group Companies, Inc.

Net retained profit for the financial year 2025 amounted to EUR 86,069k. The Supervisory board and the Management board propose to the Annual general meeting to distribute a dividend of EUR 0.18 per no-par value share (corresponding to a total dividend distribution of EUR 27,111k) and to carry forward the remaining net retained profit of EUR 58,958k. to new account.

USA Jan 8, 2025 Jan 6, 2025 3.0% 3.03% 4,567,469

24, 2025 3.0% 2.92% 4,394,299

September

Report on material events after the reporting date

Los Angeles, USA

September 25, 2025

No significant events occurred between the reporting date (September 30, 2025) and the preparation date (December 9, 2025) that would have had a material impact on the financial position and financial performance of SCHOTT Pharma KGaA.

7 EXECUTIVE BODIES OF THE COMPANY

Management board of SCHOTT Pharma Management AG, general partner of SCHOTT Pharma AG & Co. KGaA

Chairman of the Management board, SCHOTT Pharma Management AG

(on the Management board since July 15, 2022) (on the Management board since August 1, 2025)

Member of the Board of Directors, SCHOTT Glass Technologies Co. Ltd., Suzhou, China

Chairman of the Board of Directors, SCHOTT Poonawalla Pvt. Ltd., Mumbai, India

Andreas Reisse Reinhard Mayer

Member of the Management board (CFO), SCHOTT Pharma Management AG

Offices held: Offices held:

Chairman of the Board of Directors, SCHOTT Poonawalla Pvt. Ltd., Mumbai, India

Dr. Almuth Steinkühler

Member of the Management board (CFO), SCHOTT Pharma Management AG

(on the Management board until July 31, 2025)

Supervisory Board of SCHOTT Pharma AG & Co. KGaA

Chairman of the Management board, STADA Arzneimittel AG, Bad Vilbel

Chairman of the Supervisory board SCHOTT Pharma AG & Co. KGaA

Member of the Supervisory board, SCHOTT Pharma Management AG, Mainz

Peter Goldschmidt Prof. Wolfram Carius

Independent consultant

Deputy Chairman of the Supervisory board, SCHOTT Pharma AG & Co. KGaA

(on the Supervisory board since April 4, 2023) (on the Supervisory board since February 4, 2025)

Offices held: Offices held:

Member of the Supervisory board, SCHOTT Pharma Management AG, Mainz

Member of the Supervisory board, Siegfried AG, Zofingen, Switzerland

Member of the Supervisory board, Suedpack Medica AG, Baar, Switzerland

Member of the Supervisory board, Ferring Ventures (FinVector), Lausanne, Switzerland

Member of the Supervisory board, BlueRock Therapeutics LP, Berlin

Ann-Kristin Erkens Eva Kienle

Chief Financial Officer and Interim CEO, SIG Group AG, Neuhausen, Switzerland

(on the Supervisory board since April 4, 2023) (on the Supervisory board since April 4, 2023)

Chief Financial Officer, Ramboll Group A/S, Copenhagen, Denmark

Offices held: Offices held:

none Member of the Supervisory board, Zumtobel Group AG, Dornbirn, Austria

Mario Just

Member of the Employee council

Employee representative

(on the Supervisory board since April 19, 2023)

Offices held:

none

Dr. Wolfgang Wienand Christine Wening

Chief Executive Officer, Lonza AG, Basel, Switzerland

(on the Supervisory board until December 31, 2024) (on the Supervisory board until August 31, 2025)

Head of Global Supply Chain Management

Employee representative

Audit committee

Eva Kienle, Chairwoman
Ann-Kristin Erkens
Christine Wening (until August 31, 2025)

Mainz, Germany, December 9, 2025

SCHOTT Pharma AG & Co. KGaA

represented by the Management board of SCHOTT Pharma Management AG

Andreas Reisse Reinhard Mayer

LIST OF DIRECT AND INDIRECT SHAREHOLDINGS OF SCHOTT PHARMA AG & CO. KGAA AS OF SEPTEMBER 30, 2025 IN ACCORDANCE WITH SECTION 285(1) NO. 11 HGB

Name and registered office of the company			IFRS equity		IFRS result after taxes
	Shareholding (section 285 no. 11 HGB)	Local currency	Local currency	EUR *)	Local currency	EUR **)
	in %	(Local currency)	in k	in k	in k	in k
Affiliated companies
Germany
SCHOTT Pharma Mexico GmbH, Mainz, Germany	100.0	EUR	40,762	40,762	0	0
Abroad
SCHOTT Envases Argentina S.A., Buenos Aires, Argentina	100.0	ARS	14,515,500	9,199	824,694	523
SCHOTT Pharma Brasil Ltda., São Paulo, Brazil	100.0	BRL	202,499	32,493	46,617	7,3821
SCHOTT Pharmaceutical Packaging (Zhejiang) Co., Ltd., Huzhen Town, China	100.0	CNY	431,142	51,649	1,756	3091
SCHOTT France Pharma Systems SAS, Pont-sur-Yonne, France	100.0	EUR	-1,023	-1,023	-1,531	-1,531
SCHOTT Pharma France SAS, Colombes, France	100.0	EUR	10,856	10,856	-1,679	-1,679
PT. SCHOTT Igar Glass, Bekasi, Indonesia	100.0	IDR	542,292,610	27,710	212,363,593	12,047
SCHOTT Envases Farmacéuticos SAS, Bogotá, Colombia	72.7	COP	33,169,456	7,196	8,913,191	1,9311
SCHOTT de México, S.A. de C.V., Amatlán de los Reyes, Mexico	100.0	MXN	1,489,276	69,229	180,419	8,3211
SCHOTT Pharmaceutical Packaging OOO, Zavolzhye, Russia	100.0	RUB	446,496	3,862	160,719	1,6021
SCHOTT forma vitrum holding ag, St. Gallen, Switzerland	100.0	CHF	89,574	75,166	50,847	54,129
SCHOTT Pharma Schweiz AG, St Gallen, Switzerland	100.0	CHF	291,250	311,324	88,262	93,872
SCHOTT Pharma D.O.O. Jagodina, Jagodina, Serbia	100.0	RSD	1,073,458	9,161	-1,092,173	-9,325
SCHOTT Hungary Kft., Lukácsháza, Hungary	100.0	HUF	5,945,170	15,230	-5,962,132	-14,872
SCHOTT Pharma USA, Inc., Lebanon, USA	100.0	USD	102,992	87,862	24,399	22,187
Joint ventures
Abroad
SCHOTT Poonawalla Pvt. Ltd., Mumbai, India	50.0	INR	14,304,208	137,121	2,261,612	23,9592
Empha S.p.A., Turin, Italy	50.0	EUR	15,590	15,590	4,479	4,4791
Smart Skin Technologies Inc., Fredericton, Canada	20.0	CAD	10,410	6,967	122	821

¹ Financial year from January 1 to December 31

² Financial year from April 1 to March 31

^*) For companies whose accounts are in foreign currency, equity is converted using the prevailing exchange rate on the respective reporting date.

^**) For companies whose accounts are in foreign currency, profit/loss for the period is converted using the average exchange rate for the period ending on the respective reporting date.

24 Responsibility statement

RESPONSIBILITY STATEMENT

To the best of our knowledge, and in accordance with the applicable accounting principles, the Annual financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of SCHOTT Pharma AG & Co. KGaA, and the Company's Management report, which is combined with the Group management report, includes a fair review of the development and performance of the business and the position of the Company, together with a description of the principal opportunities and risks associated with the expected development of SCHOTT Pharma AG & Co. KGaA.

Andreas Reisse	Reinhard Mayer
represented by the Management board of SCHOTT Pharma Management AG
SCHOTT Pharma AG & Co. KGaA
Mainz, December 9, 2025

Independent auditor's report 25

INDEPENDENT AUDITOR'S REPORT

To SCHOTT Pharma AG & Co. KGaA, Mainz

REPORT ON THE AUDIT OF THE ANNUAL FINANCIAL STATEMENTS AND OF THE COMBINED MANAGEMENT REPORT

OPINIONS

We have audited the annual financial statements of SCHOTT Pharma AG & Co. KGaA, Mainz, which comprise the balance sheet as of September 30, 2025, and the income statement for the financial year from October 1, 2024, to September 30, 2025, and notes to the financial statements, including the recognition and measurement policies presented therein. In addition, we have audited the management report of SCHOTT Pharma AG & Co. KGaA and the Group (hereinafter "combined management report") for the financial year from October 1, 2024, to September 30, 2025.

In accordance with German legal requirements, we have not audited the content of those components of the combined management report specified in the "Other Information" section of our auditor's report.

In our opinion, on the basis of the knowledge obtained in the audit,

the accompanying annual financial statements comply, in all material respects, with the requirements of German commercial law applicable to business corporations and give a true and fair view of the assets, liabilities and financial position of the Company as of September 30, 2025, and of its financial performance for the financial year from October 1, 2024, to September 30, 2025, in compliance with German legally required accounting principles, and
the accompanying combined management report as a whole provides an appropriate view of the Company's position. In all material respects, this combined management report is consistent with the annual financial statements, complies with German legal requirements and appropriately presents the opportunities and risks of future development. Our opinion on the combined management report does not cover the content of those components of the combined management report specified in the "Other Information" section of the auditor's report.

Pursuant to Section 322 (3) sentence 1 HGB [Handelsgesetzbuch: German Commercial Code], we declare that our audit has not led to any reservations relating to the legal compliance of the annual financial statements and of the combined management report.

BASIS FOR THE OPINIONS

We conducted our audit of the annual financial statements and of the combined management report in accordance with Section 317 HGB and the EU Audit Regulation No 537/2014 (referred to subsequently as "EU Audit Regulation") and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer [Institute of Public Auditors in Germany] (IDW). Our responsibilities under those requirements and principles are further described in the "Auditor's Responsibilities for the Audit of the Annual Financial Statements and of the Combined Management Report" section of our auditor's report. We are independent of the Company in accordance with the requirements of European law and German commercial and professional law, and we have fulfilled our other German professional responsibilities in accordance with these requirements. In addition, in accordance with Article 10 (2)(f) of the EU Audit Regulation, we declare that we have not provided non-audit services prohibited under Article 5 (1) of the EU Audit Regulation. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinions on the annual financial statements and on the combined management report.

<-- PDF CHUNK SEPARATOR -->

KEY AUDIT MATTERS IN THE AUDIT OF THE ANNUAL FINANCIAL STATEMENTS

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the annual financial statements for the financial year from October 1, 2024, to September 30, 2025. These matters were addressed in the context of our audit of the annual financial statements as a whole, and in forming our opinion thereon, we do not provide a separate opinion on these matters.

Valuation of the shares in SCHOTT Pharma Mexico GmbH and SCHOTT Pharma USA, Inc.

Please refer to chapter 3 "ACCOUNTING POLICIES" of the notes to the financial statements for more information on the accounting policies applied. Movements in shares in affiliated companies are presented in chapter 4 "NOTES TO THE BALANCE SHEET" in the section "Statement of Changes in Fixed Assets for the financial year from October 1, 2024, to September 30, 2025".

THE FINANCIAL STATEMENT RISK

SCHOTT Pharma AG & Co. KGaA's annual financial statements as of September 30, 2025, present shares in affiliated companies in the amount of EUR 482.9 million (PY: EUR 484.5 million) under financial assets. These relate in particular to SCHOTT Pharma Mexico GmbH, Mainz, and SCHOTT Pharma USA, Inc., Lebanon (USA), and at approx. 59.9% of total assets, they have a significant influence on the Company's assets and liabilities.

Shares in affiliated companies are recognized at cost or, if they are expected to be permanently impaired, at their lower fair value. The Company calculates fair value using the discounted cash flow method.

The cash flows used for the discounted cash flow method are based on plans for individual investments for the next three and five years, which are adjusted using assumptions for long-term growth rates. The country-specific weighted discount rate is derived from the return on an alternative investment with comparable risk. If the fair value is lower than the carrying amount, qualitative and quantitative criteria are used to examine whether impairment is expected to be permanent. If fair value exceeds the carrying amount, the impairment loss – assuming an impairment loss was previously recognized – is reversed up to a maximum of initial cost, provided the reasons for impairment no longer apply.

The impairment testing including the calculation of the fair value according to the discounted cash flow method is complex, and the assumptions made depend to a high degree on estimates and judgments of the Company. Among other things, this applies to estimates of future cash flows and long-term growth rates, the determination of the discount rates and the assessment of whether any potential impairment is permanent or whether the reasons for impairment no longer apply.

The Company did not recognize any impairment losses or impairment reversals on the shares in SCHOTT Pharma Mexico GmbH and SCHOTT Pharma USA, Inc. in the financial year.

There is the risk for the annual financial statements that the shares in SCHOTT Pharma Mexico GmbH and SCHOTT Pharma USA, Inc. may be impaired or that required impairment reversals may not have been recognized.

OUR AUDIT APPROACH

First, we gained an understanding of the Company's process for impairment testing the shares held in affiliated companies by obtaining explanations from employees of the Controlling and Finance departments and by evaluating internal documentation. In doing so, we thoroughly examined the Company's approach to determining the need to recognize or reverse impairment and, based on the information obtained during our audit, assessed whether there were any indications of the need to recognize or reverse impairment that had not been identified by the Company.

Subsequently, with the support of our valuation specialists, we assessed the appropriateness of the key assumptions and the valuation method for the business valuations performed by the Company. To this end, we discussed the expected cash flows and the assumed long-term growth rates with those responsible for planning. We also checked whether the planning for the individual investments underlying the valuation was in line with the annual budget for 2026 drawn up by the management of SCHOTT Pharma AG & Co. KGaA and approved by the Supervisory Board and the multi-year planning for 2027 to 2028 drawn up by the management of SCHOTT Pharma AG & Co. KGaA and approved by the Supervisory Board. Furthermore, we evaluated the consistency of the assumptions with external market assessments.

We also confirmed the accuracy of the Company's previous forecasts by comparing the budgets of previous financial years with actual results and by analyzing deviations.

We compared the assumptions and data underlying the discount rate, especially the risk-free interest rate, the market risk and country risk premium, as well as the beta factor, with our own assumptions and publicly available data. In order to account for the existing forecast uncertainty, we also examined the effects of potential changes in the discount rate, expected cash flows and the terminal value growth rate on fair value by calculating alternative scenarios and comparing these with the measurements of the Company (sensitivity analysis). To assess the methodically and mathematically correct implementation of the valuation method, we verified the Company's valuation using our own calculations and analyzed deviations.

OUR OBSERVATIONS

The approach used for impairment testing the shares in SCHOTT Pharma Mexico GmbH and SCHOTT Pharma USA, Inc. is appropriate and in line with the accounting policies. The Company's assumptions, estimates and data used are appropriate.

Accrual-basis revenue recognition for product sales to third parties at financial year-end

For the accounting principles applied, please see the disclosures in chapter 3 "ACCOUNTING POLICIES" of the notes to the financial statements. Information on the amount and breakdown of revenue can be found in chapter 5 "NOTES TO THE INCOME STATEMENT".

THE FINANCIAL STATEMENT RISK

SCHOTT Pharma AG & Co. KGaA's revenue in financial year 2025 amounted to EUR 187.2 million (PY: EUR 164.4 million), of which EUR 96.6 million (PY: EUR 87.3 million) was from product sales to third parties. This corresponds to approx. 51.6% and therefore has a significant impact on the Company's financial performance.

SCHOTT Pharma AG & Co. KGaA recognizes revenue from the sale of products when the Company has transferred to the buyer the significant risks and rewards of ownership of the goods sold.

The Company's key markets are in Europe, the Middle East and Africa ("EMEA"), Asia and the South Pacific as well as North America. For deliveries of products, different delivery conditions are agreed. These conditions set down the transfer of risk and thereby determine the date of revenue recognition.

Due to the use of different contractual arrangements combined with the means of transport for each delivery and the high number of deliveries in the individual markets, there is the risk for the annual financial statements that revenue with third parties from product sales in the year under review may have been recognized too early and therefore not on an accrual basis.

OUR AUDIT APPROACH

Using inquiries and discussions with representatives from the Company's Finance and Sales departments, we obtained an understanding of the revenue recognition process. We evaluated the accounting principles used for revenue recognition for compliance with the relevant accounting standards.

In addition, based on our process understanding, we assessed the design and implementation of the internal controls relating to accrual-basis revenue recognition at financial year-end for revenue with third parties from product sales.

In accordance with the delivery conditions, the means of transport and the target market, we defined a risk-exposed period at year-end for revenue with third parties from product sales. For this revenue, we selected a representative sample referring to contract-specific details on the transfer of risk and used external proofs of delivery to verify accrual-basis revenue recognition.

OUR OBSERVATIONS

SCHOTT Pharma AG & Co. KGaA's procedure for accrual-basis recognition of revenue with third parties from product sales at year-end is appropriate.

OTHER INFORMATION

Management and/or the Supervisory Board are/is responsible for the other information. The other information comprises the following components of the combined management report, whose content was not audited:

the combined non-financial statement for the Company and the Group, which is contained in the "Nonfinancial statement" of the combined management report,
the combined corporate governance statement for the Company and the Group referred to in the combined management report, and
information extraneous to combined management reports and marked as unaudited.

Our opinions on the annual financial statements and on the combined management report do not cover the other information, and consequently we do not express an opinion or any other form of assurance conclusion thereon. In connection with our audit, our responsibility is to read the other information and, in so doing, to consider whether the other information

is materially inconsistent with the annual financial statements, with the combined management report information audited for content or our knowledge obtained in the audit, or
otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF MANAGEMENT AND THE SUPERVISORY BOARD FOR THE ANNUAL FINANCIAL STATEMENTS AND THE COMBINED MANAGEMENT REPORT

Management is responsible for the preparation of the annual financial statements that comply, in all material respects, with the requirements of German commercial law applicable to business corporations, and that the annual financial statements give a true and fair view of the assets, liabilities, financial position and financial performance of the Company in compliance with German legally required accounting principles. In addition, management is responsible for such internal control as they, in accordance with German legally required accounting principles, have determined necessary to enable the preparation of annual financial statements that are free from material misstatement, whether due to fraud (i.e., fraudulent financial reporting and misappropriation of assets) or error.

In preparing the annual financial statements, management is responsible for assessing the Company's ability to continue as a going concern. They also have the responsibility for disclosing, as applicable, matters related to going concern. In addition, they are responsible for financial reporting based on the going concern basis of accounting, provided no actual or legal circumstances conflict therewith.

Furthermore, management is responsible for the preparation of the combined management report that as a whole provides an appropriate view of the Company's position and is, in all material respects, consistent with the annual financial statements, complies with German legal requirements, and appropriately presents the opportunities and risks of future development. In addition, management is responsible for such arrangements and measures (systems) as they have considered necessary to enable the preparation of a combined management report that is in accordance with the applicable German legal requirements, and to be able to provide sufficient appropriate evidence for the assertions in the combined management report.

The Supervisory Board is responsible for overseeing the Company's financial reporting process for the preparation of the annual financial statements and of the combined management report.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE ANNUAL FINANCIAL STATEMENTS AND OF THE COMBINED MANAGEMENT REPORT

Our objectives are to obtain reasonable assurance about whether the annual financial statements as a whole are free from material misstatement, whether due to fraud or error, and whether the combined management report as a whole provides an appropriate view of the Company's position and, in all material respects, is consistent with the annual financial statements and the knowledge obtained in the audit, complies with the German legal requirements and appropriately presents the opportunities and risks of future development, as well as to issue an auditor's report that includes our opinions on the annual financial statements and on the combined management report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Section 317 HGB and the EU Audit Regulation and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer (IDW) will always detect a material misstatement. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial statements and this combined management report.

We exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the annual financial statements and of the combined management report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than the risk of not detecting a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
Obtain an understanding of internal control relevant to the audit of the annual financial statements and of arrangements and measures relevant to the audit of the combined management report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control or of these arrangements and measures.
Evaluate the appropriateness of accounting policies used by management and the reasonableness of estimates made by management and related disclosures.
Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the related disclosures in the annual financial statements and in the combined management report or, if such disclosures are inadequate, to modify our respective opinions. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to be able to continue as a going concern.
Evaluate the overall presentation, structure and content of the annual financial statements, including the disclosures, and whether the annual financial statements present the underlying transactions and events in a manner that the annual financial statements give a true and fair view of the assets, liabilities, financial position and financial performance of the Company in compliance with German legally required accounting principles.
Evaluate the consistency of the combined management report with the annual financial statements, its conformity with [German] law, and the view of the Company's position it provides.
Perform audit procedures on the prospective information presented by management in the combined management report. On the basis of sufficient appropriate audit evidence we evaluate, in particular, the significant assumptions used by management as a basis for the prospective information, and evaluate the proper derivation of the prospective information from these assumptions. We do not express a separate opinion on the prospective information and on the assumptions used as a basis. There is a substantial unavoidable risk that future events will differ materially from the prospective information.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with the relevant independence requirements, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, the actions taken or safeguards applied to eliminate independence threats.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the annual financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter.

OTHER LEGAL AND REGULATORY REQUIREMENTS

Report on the Assurance on the Electronic Rendering of the Annual Financial Statements and the Combined Management Report Prepared for Publication Purposes in Accordance with Section 317 (3a) HGB

OPINION

We have performed assurance work in accordance with Section 317 (3a) HGB to obtain reasonable assurance about whether the rendering of the annual financial statements and the combined management report (hereinafter the "ESEF documents") contained in the electronic file "JA.xhtml" (SHA256-hash value: 56430c26e723422f4b4b 2921797be985d15a503deec823ac9033c0300ed26275) made available and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format ("ESEF format"). In accordance with German legal requirements, this assurance work extends only to the conversion of the information contained in the annual financial statements and the combined management report into the ESEF format and therefore relates neither to the information contained within these renderings nor to any other information contained in the file identified above.

In our opinion, the rendering of the annual financial statements and the combined management report contained in the electronic file made available identified above and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format. Beyond this assurance opinion and our audit opinion on the accompanying annual financial statements and the accompanying combined management report for the financial year from October 1, 2024, to September 30, 2025, contained in the "Report on the Audit of the Annual Financial Statements and of the Combined Management Report" above, we do not express any assurance opinion on the information contained within these renderings or on the other information contained in the file identified above.

BASIS FOR THE OPINION

We conducted our assurance work on the rendering of the annual financial statements and the combined management report, contained in the file made available and identified above in accordance with Section 317 (3a) HGB and the IDW Assurance Standard: Assurance Work on the Electronic Rendering of Financial Statements and Management Reports Prepared for Publication Purposes in Accordance with Section 317 (3a) HGB (IDW AsS 410 (06.2022)) and the International Standard on Assurance Engagements 3000 (Revised). Our responsibility in accordance therewith is further described in the "Responsibilities of the Auditor for the Assurance Work on the ESEF Documents" section. Our audit firm applies the IDW Standard on Quality Management 1: Requirements for Quality Management in Audit Firms (IDW QMS 1 (09.2022)).

RESPONSIBILITIES OF MANAGEMENT AND THE SUPERVISORY BOARD FOR THE ESEF DOCUMENTS

The Company's management is responsible for the preparation of the ESEF documents including the electronic renderings of the annual financial statements and the combined management report in accordance with Section 328 (1) sentence 4 item 1 HGB.

In addition, the Company's management is responsible for such internal control as they have considered necessary to enable the preparation of ESEF documents that are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB for the electronic reporting format.

The Supervisory Board is responsible for overseeing the process of preparing the ESEF documents as part of the financial reporting process.

RESPONSIBILITIES OF THE AUDITOR FOR THE ASSURANCE WORK ON THE ESEF DOCUMENTS

Our objective is to obtain reasonable assurance about whether the ESEF documents are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB. We exercise professional judgment and maintain professional skepticism throughout the assurance work. We also:

Identify and assess the risks of material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB, design and perform assurance procedures responsive to those risks, and obtain assurance evidence that is sufficient and appropriate to provide a basis for our assurance opinion.
Obtain an understanding of internal control relevant to the assurance on the ESEF documents in order to design assurance procedures that are appropriate in the circumstances, but not for the purpose of expressing an assurance opinion on the effectiveness of these controls.
Evaluate the technical validity of the ESEF documents, i.e. whether the file made available containing the ESEF documents meets the requirements of Commission Delegated Regulation (EU) 2019/815, as amended as of the reporting date, on the technical specification for this electronic file.
Evaluate whether the ESEF documents provide an XHTML rendering with content equivalent to the audited annual financial statements and the audited combined management report.

FURTHER INFORMATION PURSUANT TO ARTICLE 10 OF THE EU AUDIT REGULATION

We were elected as auditor at the Annual General Meeting on February 4, 2025. We were engaged by the Supervisory Board on May 8, 2025. We have been the auditor of SCHOTT Pharma AG & Co. KGaA without interruption since financial year 2025.

We declare that the opinions expressed in this auditor's report are consistent with the additional report to the Audit Committee pursuant to Article 11 of the EU Audit Regulation (long-form audit report).

OTHER MATTER – USE OF THE AUDITOR'S REPORT

Our auditor's report must always be read together with the audited annual financial statements and the audited combined management report as well as the examined ESEF documents. The annual financial statements and the combined management report converted into ESEF format – including the versions to be entered in the German Company Register [Unternehmensregister] – are merely electronic renderings of the audited annual financial statements and the audited combined management report and do not take their place. In particular, the ESEF report and our assurance opinion contained therein are to be used solely together with the examined ESEF documents provided in electronic form.

GERMAN PUBLIC AUDITOR RESPONSIBLE FOR THE ENGAGEMENT

The German Public Auditor responsible for the engagement is Matthias Forstreuter.

Frankfurt am Main, December 9, 2025

KPMG AG Wirtschaftsprüfungsgesellschaft

[signature] Forstreuter [signature] Dolibasic Wirtschaftsprüfer Wirtschaftsprüferin

[German Public Auditor] [German Public Auditor]

32 Imprint

IMPRINT

DISCLAIMER/FORWARD-LOOKING STATEMENTS

These Annual financial statements contain numerous forward-looking statements which are based on the Company's assumptions, expectations and intentions. Such statements are indicated by words like "expect", "assume", "intend" or similar wording and are based both on the information currently available to management and on the prevailing environment. These may change at any time. The Company accepts no liability for the ultimate correctness and accuracy of any expectations or assumptions expressed in this report. The Company also undertakes no obligation to update any of its forward-looking statements to bring them in line with actual developments after these Annual financial statements have been published.

PUBLICATION

These Annual financial statements were published on December 11, 2025. The document is also available in German. In the event of any discrepancies, the German version shall be authoritative and prevail over the English translation.

In the interest of sustainability, the Company's annual reports, interim reports and annual financial statements are not available in printed form. We provide all reports online, as well as for download in PDF format.

ROUNDING, LANGUAGE AND FORMATTING

Due to rounding, individual figures in this document and in other documents may not correspond exactly to the totals stated and percentages shown may not exactly reflect the absolute values to which they relate.

It is also possible that, for technical reasons, the formatting of the accounting records contained in this document deviates from that of records published in accordance with statutory provisions.

Where the masculine form is used in this document, the information nevertheless refers to all persons (male, female, diverse).

CREDITS

Website: www.schott-pharma.com

Investor Relations: www.schott-pharma.com/investor-relations

Media: www.schott-pharma.com/en/news-and-media Translation: LanguageWire GmbH, Hamburg, Germany

Photography: SCHOTT AG

PUBLISHER

SCHOTT Pharma AG & Co. KGaA Hattenbergstrasse 10 55122 Mainz, Germany

AI Terminal

Schott Pharma

6514_10-k_2025-12-10_1171c664-c832-4352-a348-ed17d73037c8.pdf

Contents

COMBINED MANAGEMENT REPORT FOR THE FINANCIAL YEAR 2025

BALANCE SHEET AS OF SEPTEMBER 30, 2025

INCOME STATEMENT FOR THE FINANCIAL YEAR FROM OCTOBER 1, 2024 TO SEPTEMBER 30, 2025

NOTES TO THE ANNUAL FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR 2025

1 GENERAL INFORMATION

2 REGISTRATION INFORMATION

3 ACCOUNTING POLICIES

4 NOTES TO THE BALANCE SHEET

Receivables and other assets

Deferred tax assets

Equity

Disclosures on non-distributable amounts

Provisions for pensions and similar commitments

Provisions for taxes

Other provisions

Liabilities

5 NOTES TO THE INCOME STATEMENT

Other operating income

Personnel expenses

Other operating expenses

Income from investments

Income from long-term loans

Impairment of financial assets

Net interest result

Income taxes

6 OTHER INFORMATION

Contingencies

Other financial obligations/Off-balance sheet transactions

Average number of employees

Auditor's fee

Related party transactions

General partner

Consolidated financial statements

Declaration of Compliance pursuant to section 161 AktG

Notifications of shareholdings in SCHOTT Pharma AG & Co. KGaA

Appropriation of profits

Report on material events after the reporting date

7 EXECUTIVE BODIES OF THE COMPANY

Andreas Reisse Reinhard Mayer

Offices held: Offices held:

Dr. Almuth Steinkühler

Peter Goldschmidt Prof. Wolfram Carius

Offices held: Offices held:

Ann-Kristin Erkens Eva Kienle

Offices held: Offices held:

Mario Just

Offices held:

Dr. Wolfgang Wienand Christine Wening

Audit committee

SCHOTT Pharma AG & Co. KGaA

LIST OF DIRECT AND INDIRECT SHAREHOLDINGS OF SCHOTT PHARMA AG & CO. KGAA AS OF SEPTEMBER 30, 2025 IN ACCORDANCE WITH SECTION 285(1) NO. 11 HGB

RESPONSIBILITY STATEMENT

INDEPENDENT AUDITOR'S REPORT

OPINIONS

BASIS FOR THE OPINIONS

KEY AUDIT MATTERS IN THE AUDIT OF THE ANNUAL FINANCIAL STATEMENTS

Valuation of the shares in SCHOTT Pharma Mexico GmbH and SCHOTT Pharma USA, Inc.

THE FINANCIAL STATEMENT RISK

OUR AUDIT APPROACH

OUR OBSERVATIONS

Accrual-basis revenue recognition for product sales to third parties at financial year-end

THE FINANCIAL STATEMENT RISK

OUR AUDIT APPROACH

OUR OBSERVATIONS

OTHER INFORMATION

RESPONSIBILITIES OF MANAGEMENT AND THE SUPERVISORY BOARD FOR THE ANNUAL FINANCIAL STATEMENTS AND THE COMBINED MANAGEMENT REPORT

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE ANNUAL FINANCIAL STATEMENTS AND OF THE COMBINED MANAGEMENT REPORT

OTHER LEGAL AND REGULATORY REQUIREMENTS

OPINION

BASIS FOR THE OPINION

RESPONSIBILITIES OF MANAGEMENT AND THE SUPERVISORY BOARD FOR THE ESEF DOCUMENTS

RESPONSIBILITIES OF THE AUDITOR FOR THE ASSURANCE WORK ON THE ESEF DOCUMENTS

FURTHER INFORMATION PURSUANT TO ARTICLE 10 OF THE EU AUDIT REGULATION

OTHER MATTER – USE OF THE AUDITOR'S REPORT

GERMAN PUBLIC AUDITOR RESPONSIBLE FOR THE ENGAGEMENT

IMPRINT